360 Results

People

  1. Lacouture
    Lacouture
  2. Panageas
    Panageas
  3. Wolchok
    Wolchok
  4. Motzer
    Motzer
  5. Postow
    Postow
  6. Houghton
    Houghton
  7. Zelenetz
    Zelenetz
  8. Balagula
    Balagula
  9. Livingston
    Livingston
  10. Aghajanian
    Aghajanian

Groups

  1. Department of Medicine (267)
  2. Solid Tumor Oncology Division (171)
  3. Survivorship Research (88)
  4. Division of Subspecialty Medicine (79)
  5. Hematologic Malignancies, Division of (71)
  6. Dermatology (65)
  7. Dermatology Service (63)
  8. GSK Faculty (53)
  9. Melanoma Disease Management Team (47)
  10. Melanoma and Immunotherapeutics Service (47)
  1. "pruritus"
Formats
  1. Journal Article (336)
  2. Review (15)
  3. Research Letter (3)
  4. Editorial (2)
  5. Miscellaneous (2)
  6. Conference Paper (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (267)
  2. Solid Tumor Oncology Division (171)
  3. Survivorship Research (88)
  4. Division of Subspecialty Medicine (79)
  5. Hematologic Malignancies, Division of (71)
  6. Dermatology (65)

More Groups

People
  1. Mario Lacouture (44)
  2. Jedd Wolchok (29)
  3. Katherine Panageas (16)
  4. Paul Chapman (16)
  5. Robert Motzer (14)
  6. Michael Postow (11)

More People

Years
  1. 2025 (11)
  2. 2024 (38)
  3. 2023 (28)
  4. 2022 (12)
  5. 2021 (16)
  6. 2020 (24)

More Years

Publications
  1. Lancet Oncology (30)
  2. Clinical Cancer Research (17)
  3. Journal of Clinical Oncology (17)
  4. Cancer (11)
  5. Journal of the American Academy of Dermatology (11)
  6. Annals of Oncology (9)

More Publications

Publishers
  1. Elsevier Inc. (46)
  2. Elsevier Science, Inc. (39)
  3. Springer (26)
  4. Nature Publishing Group (22)
  5. American Association for Cancer Research (20)
  6. American Society of Clinical Oncology (18)

More Publishers

Results (360)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes and toxicities after proton partial breast radiotherapy for early stage, hormone receptor positive breast cancer: 3-Year results of a phase II multi-center trial
    Journal Article

    Choi, J. I.; Prabhu, K.; Hartsell, W. F.; DeWees, T.; Sinesi, C.; Vargas, C.; Benda, R. K.; Cahlon, O.; Chang, A. L.
    Clinical and Translational Radiation Oncology (2022)

    Fulltext@MSK | Save
  • Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: Clinical and immunologic analyses from the randomized phase 2 PRINCE trial
    Journal Article

    Padrón, L. J.; Maurer, D. M.; O’Hara, M. H.; O’Reilly, E. M.; Wolff, R. A.; Wainberg, Z. A.; Ko, A. H.; Fisher, G.; Rahma, O.; Lyman, J. P.; more...
    Nature Medicine (2022)

    Fulltext@MSK | Save
  • Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: Final results from the BFORE trial
    Journal Article

    Brümmendorf, T. H.; Cortes, J. E.; Milojkovic, D.; Gambacorti-Passerini, C.; Clark, R. E.; le Coutre, P.; Garcia-Gutierrez, V.; Chuah, C.; Kota, V.; Lipton, J. H.; more...
    Leukemia (2022)

    Fulltext@MSK | Save
  • Metformin for treatment of cytopenias in children and young adults with Fanconi anemia
    Journal Article

    Pollard, J. A.; Furutani, E.; Liu, S.; Esrick, E.; Cohen, L. E.; Bledsoe, J.; Liu, C. W.; Lu, K.; de Haro, M. J. R.; Surrallés, J.; more...
    Blood Advances (2022)

    Fulltext@MSK | Save
  • Simplified graded infusion strategy for mitigation of oxaliplatin hypersensitivity
    Journal Article

    Alonso Martinez, S.; Segal, N. H.; Cercek, A.; Yaeger, R.; Stadler, Z.; Kemeny, N. E.; Nusrat, M.; Shahrokni, A.; Connell, L.; Saltz, L. B.
    Clinical Colorectal Cancer (2022)

    Fulltext@MSK | Save
  • Intrathecal drug delivery systems survey: Trends in utilization in pain practice
    Journal Article

    Abd-Sayed, A.; Fiala, K.; Weibstein, J.; Chopra, P.; Lam, C.; Kalia, H.; Jassal, N.; Gulati, A.; Sayed, D.; Deer, T.
    Journal of Pain Research (2022)

    Fulltext@MSK | Save
  • Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): Final analysis of a randomised, open-label, phase 3 study
    Journal Article

    Diaz, L. A. Jr; Shiu, K. K.; Kim, T. W.; Jensen, B. V.; Jensen, L. H.; Punt, C.; Smith, D.; Garcia-Carbonero, R.; Benavides, M.; Gibbs, P.; more...
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: Clinical outcomes and translational biomarker analyses
    Journal Article

    Friedman, C. F.; Spencer, C.; Cabanski, C. R.; Panageas, K. S.; Wells, D. K.; Ribas, A.; Tawbi, H.; Tsai, K.; Postow, M.; Shoushtari, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Phase I/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring
    Journal Article

    Stewart, C. M.; Michaud, L.; Whiting, K.; Nakajima, R.; Nichols, C.; De Frank, S.; Hamlin, P. A. Jr; Matasar, M. J.; Gerecitano, J. F.; Drullinsky, P.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers
    Journal Article

    Yarchoan, M.; Cope, L.; Ruggieri, A. N.; Anders, R. A.; Noonan, A. M.; Goff, L. W.; Goyal, L.; Lacy, J.; Li, D.; Patel, A. K.; more...
    Journal of Clinical Investigation (2021)

    Fulltext@MSK | Save